Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV/AIDS who are taking antiretroviral therapy
- PMID: 21232913
- PMCID: PMC3041636
- DOI: 10.1016/j.jpainsymman.2010.05.011
Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV/AIDS who are taking antiretroviral therapy
Abstract
Context: Muscle aches, numbness in the feet/toes (neuropathy), and fatigue are often reported concurrently and are among the symptoms most frequently reported by individuals with HIV/AIDS, whether or not they are taking antiretroviral therapy (ART).
Objectives: This study used a longitudinal analytical methodology to analyze these symptoms together to determine whether symptom clusters are maintained over time and to determine whether there is a temporal relationship between fatigue and reports of neuropathic pain and muscle aches.
Methods: This was a secondary analysis of a subset of data from a six-month, longitudinal, randomized, controlled trial of 243 HIV-positive individuals taking ART. Self-reported symptom frequency and intensity were recorded using the Revised Sign and Symptom Checklist for Persons with HIV disease at baseline (Month 0), one, three, and six months. Multilevel, logistic regression models were used to analyze time-lagged effects of muscle aches, numbness of the feet/toes, and fatigue to estimate any predictive and interactive effects that the symptoms have upon one another.
Results: A significant relationship between muscle aches and fatigue intercepts was noted (odds ratio [OR]=1.80, P≤0.05). Significant relationships between numbness and fatigue also were noted for the entire measurement period (OR=2.70, P≤0.05). Time-lagged models showed persons reporting neuropathic-related numbness in one period were nearly twice as likely to report fatigue in subsequent periods (OR=1.89, P≤0.05). The final model revealed that the addition of muscle aches and numbness explained 28% of the random variance in the occurrence of fatigue. Between-person descriptive variables including years living with HIV, age, having an AIDS diagnosis, ethnicity, and nucleoside reverse transcriptase inhibitor treatment regimens with stavudine, zalactabine, or didanosine did not significantly explain any additional model variation.
Conclusion: These findings are consistent with physiological research and provide evidence that analyzing multiple symptom change over time can provide a more accurate representation of an individual's symptom experience. When evaluating patients with muscle aches or numbness, particularly when both symptoms are present, an evaluation of fatigue should be considered. Similarly, if fatigue is reported, underlying physiological assessments for neuropathic symptoms and muscle aches may be considered.
Copyright © 2011 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF.Patient. 2015 Aug;8(4):359-71. doi: 10.1007/s40271-015-0129-9. Patient. 2015. PMID: 26045359 Free PMC article. Clinical Trial.
-
Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.J Manag Care Pharm. 2011 Apr;17(3):213-23. doi: 10.18553/jmcp.2011.17.3.213. J Manag Care Pharm. 2011. PMID: 21434698 Free PMC article.
-
Patterns of change in symptom clusters with HIV disease progression.J Pain Symptom Manage. 2011 Jul;42(1):12-23. doi: 10.1016/j.jpainsymman.2010.09.021. Epub 2011 Mar 23. J Pain Symptom Manage. 2011. PMID: 21429701 Free PMC article.
-
Alcohol Use and Antiretroviral Therapy Non-Adherence Among Adults Living with HIV/AIDS in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.AIDS Behav. 2020 Jun;24(6):1727-1742. doi: 10.1007/s10461-019-02716-0. AIDS Behav. 2020. PMID: 31673913 Free PMC article.
Cited by
-
Identifying mediating variables with graphical models: an application to the study of causal pathways in people living with HIV.J Appl Stat. 2019 Sep 21;47(7):1298-1314. doi: 10.1080/02664763.2019.1669543. eCollection 2020. J Appl Stat. 2019. PMID: 35707027 Free PMC article.
-
Fatigue in HIV-Infected People: A Three-Year Observational Study.J Pain Symptom Manage. 2015 Jul;50(1):69-79. doi: 10.1016/j.jpainsymman.2015.02.006. Epub 2015 Feb 18. J Pain Symptom Manage. 2015. PMID: 25701691 Free PMC article.
-
Association Between HIV Symptom Burden and Inflammatory Cytokines: An Analysis by Sex and Menopause Stage.J Womens Health (Larchmt). 2020 Jan;29(1):119-127. doi: 10.1089/jwh.2019.7749. Epub 2019 Aug 21. J Womens Health (Larchmt). 2020. PMID: 31433243 Free PMC article.
-
HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress.J Pain Symptom Manage. 2022 Jun;63(6):943-952. doi: 10.1016/j.jpainsymman.2022.02.337. Epub 2022 Feb 27. J Pain Symptom Manage. 2022. PMID: 35235857 Free PMC article.
References
-
- Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45(5):394–402. - PubMed
-
- Bonfanti P, Ricci E, Landonio S, et al. Predictors of protease inhibitor-associated adverse events. Biomed Pharmacother. 2001;55(6):321–323. - PubMed
-
- Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 200;19(2):124–133. - PubMed
-
- Holzemer WL. HIV and AIDS: the symptom experience. What cell counts and viral loads won’t tell you. Am J Nurs. 2002;102(4):48–52. - PubMed
-
- Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18(4):253–262. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical